Participation in clinical trials high among gay, lesbian and bisexual cancer survivors

October 30, 2012

Cancer survivors who self-identified as being lesbian, gay or bisexual were more than twice as likely as heterosexual cancer survivors to have participated in cancer clinical trials, according to data from a small study presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

"The data from which our findings were derived were incredibly limited. We have to interpret these data cautiously," said Jennifer M. Jabson, M.P.H., Ph.D., a postdoctoral research fellow in the department of community health sciences at Boston University School of Public Health.

In 2011, the Institute of Medicine (IOM) issued a report titled "The Health of Lesbian, Gay, Bisexual and Transgender People: Building a Foundation for Better Understanding," in which it identified this community as medically underserved. Jabson and colleagues studied the representation of the lesbian, gay and bisexual community in to add to existing knowledge about their experience with and their participation in the clinical trial system.

The researchers used data from the and an optional module that assesses cancer survivor participation in cancer . They collected data from five states—Massachusetts, New Mexico, Wisconsin, Alaska and California—that used this module and an item asking self-identified lesbian, gay and bisexual status. The total population was 4,339 people.

"We thought there would be an under-representation of lesbian, gay and in the data," Jabson said. "We only found one prior paper that had been published in the last 10 years on the topic, and it found that individuals in this community were more often excluded in all clinical trials, not just those specific to cancer."

However, the results of this study indicated that 12.5 percent of the cancer survivor population that self-identified as being lesbian, gay and bisexual participated in clinical trials compared with 6 percent of the heterosexual cancer survivor population. When adjusting the data to account for participants' age, sex, education, race/ethnicity and survey location, from the lesbian, gay and bisexual community were more than twice as likely to report participation in a clinical trial.

Jabson said it is difficult to infer an explanation for these findings.

"We need to replicate our findings in a larger and more comprehensive sample to explore some of the causal or explanatory variables and to make sure that the result was not an artifact of the sample," she said. "In addition, we agree with the IOM report that sexual orientation should be collected as a demographic variable in population-based health surveillance systems and cancer registries."

Additional studies are warranted to explain the greater representation of individuals who self-identify as lesbian, gay and bisexual in cancer survivor clinical trials and potentially to identify ways to prevent and treat cancer in this community, according to Jabson.

Explore further: Sexual orientation affects cancer survivorship

Related Stories

Sexual orientation affects cancer survivorship

May 9, 2011
Gay men have a higher prevalence of cancer compared with heterosexual men, and lesbian and bisexual female cancer survivors report lower levels of health than heterosexual female cancer survivors. Those are the conclusions ...

Supporting LGB children may influence their long-term health, study finds

April 10, 2012
'Coming out' as gay, lesbian or bisexual may be good for your health, particularly when parental support is involved.

Bisexual women, more likely than bisexual men, to be depressed and abuse alcohol, new study finds

November 8, 2011
Bisexual women are more likely than their male counterparts to suffer from depression and stress and to binge-drink, according to a new national study led by George Mason University researcher Lisa Lindley.

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Powerful drug combo gangs up to tackle triple-negative breast cancer

September 26, 2017
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death.

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.